The treatment with EGFR-inhibitors is currently in clinical practice, having demonstrated important anti-tumor activity in patients with head and neck squamous cell carcinoma, metastatic colorectal cancer, lung cancer as well as breast cancer. Here, EGFR is linked to neoplasm.